159 related articles for article (PubMed ID: 10820360)
41. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?
Spazzapan S; Crivellari D; Lombardi D; Scuderi C; Magri MD; Veronesi A; Gatti A
J Clin Oncol; 2002 Nov; 20(21):4404-5; author reply 4405. PubMed ID: 12409345
[No Abstract] [Full Text] [Related]
42. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
43. [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Moiseenko VM; O'Reilly SM; Dalbot DC; Van Belle S; Gordon RJ; Griffin T; Osterwalder B
Vopr Onkol; 2000; 46(3):285-9. PubMed ID: 10976273
[TBL] [Abstract][Full Text] [Related]
44. One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index.
Seidman AD
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):19-22. PubMed ID: 9516598
[TBL] [Abstract][Full Text] [Related]
45. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?
Maisano R; Mare M; Zavettieri M; Caristi N; Mesiti M; Scisca C; La Torre F
Anticancer Res; 2003; 23(2C):1923-6. PubMed ID: 12820480
[TBL] [Abstract][Full Text] [Related]
46. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
47. A pilot clinical laboratory trial of paclitaxel and endobronchial brachytherapy in patients with non-small cell lung cancer.
Lee JS; Komaki R; Morice RC; Ro JY; Kalapurakal SK; Schea R; Murphy WK; Shin DM; Fox NT; Walsh GL; Hittelman WN; Hong WK
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):121-9. PubMed ID: 10210551
[TBL] [Abstract][Full Text] [Related]
48. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
[TBL] [Abstract][Full Text] [Related]
49. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
50. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
51. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
52. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Sato K; Inoue K; Saito T; Kai T; Mihara H; Okubo K; Koh J; Mochizuki H; Tabei T;
Jpn J Clin Oncol; 2003 Aug; 33(8):371-6. PubMed ID: 14523055
[TBL] [Abstract][Full Text] [Related]
53. Epistaxis during treatment with paclitaxel.
Yarom N; Cyjon A; Kovel S; Yachnin A; Sella A; Evron E
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):259-61. PubMed ID: 19191781
[TBL] [Abstract][Full Text] [Related]
54. [Taxane-induced ungual anomalies].
Schmutz JL; Barbaud A; Tréchot P
Ann Dermatol Venereol; 2000 Jan; 127(1):130. PubMed ID: 10717580
[No Abstract] [Full Text] [Related]
55. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
56. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
57. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
Taghian AG; Assaad SI; Niemierko A; Kuter I; Younger J; Schoenthaler R; Roche M; Powell SN
J Natl Cancer Inst; 2001 Dec; 93(23):1806-11. PubMed ID: 11734597
[TBL] [Abstract][Full Text] [Related]
58. [Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
Uno Y; Hirano M; Murakami N; Kikuchi T; Nozawa H; Okuda T; Oya J; Kikkawa H
Gan To Kagaku Ryoho; 2002 Feb; 29(2):227-32. PubMed ID: 11865628
[TBL] [Abstract][Full Text] [Related]
59. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
60. Docetaxel-induced nail dystrophy.
Nicolopoulos J; Howard A
Australas J Dermatol; 2002 Nov; 43(4):293-6. PubMed ID: 12423438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
